Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer

Official title

Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Her-2 Negative Unresectable Locally Advanced Gastric Cancer: a National Multicenter Randomized Controlled Study

Overview

To investigate the clinical efficacy and safety of envollizumab combined with fruquintinib and SOX versus SOX in conversion therapy for patients with Her-2 negative, unresectable locally advanced gastric cancer.

Interventions

• Drug Envolimab
  Envolizumab 300mg, D1, ih, Q3W 4-6cycles
• Drug Fruquintinib
  Fruquinitinib 3mg/d, QD, PO, D1-D14, Q3W 4-6cycles
• Drug Oxaliplatin
  Oxaliplatin 130 mg/m2, ivgtt 0-2h, D1, Q3W 4-6cycles
• Drug Tegafur
  Tegafur was calculated according to body surface area , P.O., bid, d1-d14#And the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time Q3W 4-6cycles

Primary outcome measures

• Surgical conversion rate [Time frame: 2-3 months]

Secondary outcome measures (10)

• Pathological complete response (pCR) [Time frame: 4 months]
• Median disease free survival (DFS) time [Time frame: 3 years]
• 1-year DFS rate [Time frame: 1 year]
• 3-year DFS rate [Time frame: 3 years]
• Objective response rate (ORR) [Time frame: 4 months]
• Major pathological response rate (MPR) [Time frame: 4 months]
• R0 resection rate [Time frame: 2-3 month]
• Median survival time [Time frame: 3 years]
• Adverse event (AEs) [Time frame: 2 years]
• Quality of life (QOL) [Time frame: 2 years]

Eligibility criteria

Inclusion criteria

• Age: 18-75 years of age;
• Pathological (including histological or cytological) confirmation of gastric adenocarcinoma;
• Before surgery, CT/MRI, PET-CT, if necessary, laparoscopic exploration to determine the clinical stage of T4bN0M0 and TanyN2-3M0, and determined by researchers that the local advanced patients can not be resectable;
• At least one measurable detected by CT examination in accordance with the RECIST1.1
• ECOG#Eastern Cooperative Oncology Group#PS#Performance Status#:0-1 scores;
• The expected survival time is more than 3 months
• The main organ function is normal, which should meet the following criteria:

#1#blood routine examination standards should be met#no blood transfusion within 14 days#

a.HB≥ 100g/L b. WBC≥3×109/L c. ANC≥1.5×109/L d. PLT≥100×109/L #2#biochemical examination shall comply with the following criteria#

• BIL#1.5 normal upper limit ULN
• ALT and AST#2.5 ULN
• Cr≤1 ULN#CCR#creatinine clearance rate##60ml/min(Cockcroft Gault formula)
• Women of childbearing age must have a pregnancy test in 7 days before entering the group (in serum), and the results were negative, and willing to use appropriate contraception during the study period and the last 8 weeks after giving drug test; men should have the surgical sterilization, or adopt the appropriate contraceptive methods during the test and the last 8 weeks after giving drug test#
• No other clinical studies were conducted before and during the treatment
• Participants is willing to participate in this study, sign the informed consent, have good compliance, cooperate with follow-up

Exclusion criteria

• Imaging or intraoperative exploration found patients with peritoneum, liver, lung and other distant metastases
• Patients with allergies or suspected allergies to study drugs or similar drugs
• Confirmed HER-2 positive patients
• Other malignancies in the past 5 years, except basal cell or squamous cell carcinoma of the skin after radical surgery, or carcinoma in situ of the cervix
• Live vaccine was administered within 4 weeks prior to enrolling or possibly during the study period
• Had an active autoimmune disease or a history of autoimmune disease within 4 weeks prior to enrollment
• Past recipients of allogeneic bone marrow transplants or organ transplants
• Patient has any current disease or condition that affects drug absorption, or the patient is unable to take the drug orally
• The blood pressure of patients with hypertension cannot be reduced to the normal range by the one antihypertensive drugs (systolic pressure ≥150 mmHg, diastolic pressure ≥100 mmHg) or hard to controled by two or more antihypertensive drugs
• Patients are positive of urine protein (urine protein detection 2+ or above, or 24 hours urine protein quantitative >1.0g)
• The patient currently has gastrointestinal diseases such as active gastric and duodenal ulcers, ulcerative colitis, or active bleeding from unresectosed tumors, or other conditions determined by researchers that may cause gastrointestinal bleeding or perforation
• Patients with significant evidence or history of bleeding tendency within 3 months prior to enrollment (bleeding within 3 months >30 mL, hematemesis, black stool, blood in stool), hemoptysis (within 4 weeks >5 mL fresh blood) or a thromboembolic event (including stroke and/or transient ischemic attack) within 12 months
• Cardiovascular disease of significant clinical significance, including but not limited to acute myocardial infarction, severe/unstable angina, or coronary artery bypass grafting within 6 months prior to enrollment; New York Heart Association (NYHA) Grades for Congestive Heart Failure more than class II ; Ventricular arrhythmias requiring medical treatment; An electrocardiogram (ECG) showed a QT c interval ≥480 milliseconds
• Active or uncontrolled severe infection (≥CTCAE grade 2 infection)
• A history of human immunodeficiency virus (HIV) infection or clinically significant liver disease, including viral hepatitis \[active HBV infection must be ruled out as a known carrier of hepatitis B virus (HBV), i.e. positive HBV DNA (>1×104 copies /mL or >2000 IU/ml); known hepatitis C virus infection (HCV) and HCV RNA positive (>1×103 copies /mL), or other hepatitis, cirrhosis\]
• The researchers consider those who were not suitable for inclusion

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Open label

Primary purpose

Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT05914610 · FUGES-028

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗